Guggenheim analyst Brad Canino initiated coverage of CG Oncology (CGON) with a Buy rating and $90 price target The firm sees CG “rising to the top of quality oncology ideas” The non-muscle invasive bladder cancer market has lots of patients and pricing power, the analyst tells investors in a research note. Guggenheim highlights the “best-in-class” efficacy and safety durability of CG’s cretostimogene, which will enter FDA review in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology price target raised to $47 from $41 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- CG Oncology price target raised to $79 from $56 at Morgan Stanley
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Buy Rating for CG Oncology: Creto’s Market Potential and Strategic Pricing Flexibility